Is Revvity, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Revvity, Inc. has moved from fair to very expensive, indicating a significant concern regarding its current pricing relative to its financial metrics. The company is considered overvalued, especially given its P/E ratio of 33, which is notably higher than peers such as Hologic, Inc. with a P/E of 21.83 and The Cooper Companies at 34.28. Additionally, Revvity's EV to EBITDA stands at 15.29, which is also above the industry average, further supporting the overvaluation stance.
In comparison to its peers, Revvity's PEG ratio of 3.05 suggests that its growth is not justifying its current price, as Hologic's PEG is significantly lower at 2.60. The company's return on equity (ROE) of 4.30% and return on capital employed (ROCE) of 4.39% are relatively low, indicating inefficiencies in generating returns from its capital. Furthermore, while Revvity has outperformed the S&P 500 in the short term with a 1-week return of 5.81% compared to 1.70%, its longer-term performance shows a concerning trend with a year-to-date return of -16.30% versus the S&P 500's 13.30%.